Gastric Cancer Clinical Trial
— SINGOfficial title:
A Randomized Clinical Trial of Simplified Dietary Education Versus Intensive Dietary Education on Nutritional Status After Gastrectomy
Radical gastrectomy has been known as the most effective treatment of curable gastric cancer.However, there is a high risk of malnutrition and weight loss after a gastrectomy which may be attributed to inadequate oral consumption, malabsorption and loss of the reservoir function of the stomach.Weight loss has been regarded as an independent risk factor for postoperative mortality and morbidity and It is also closely associated with a quality of life after surgery. No specific surgical technique has been proved to be effective in reducing postoperative weight loss and it seems like that dietary education and consultation is the best way to minimize weight loss in gastrectomy patients in clinical setting. In this regard, the investigators performed a retrospective pilot study to identify the effect of routinely performed (simplified) dietary education on nutritional status after gastrectomy, but it revealed that the effect of simplified dietary education on weight loss was not clear and the result implies that more intensive dietary education may be necessary after gastrectomy. The aim of this randomized controlled trial (RCT) is to elucidate the effect of intensive dietary education on nutritional status after gastrectomy in comparison with simplified dietary education.
Status | Recruiting |
Enrollment | 358 |
Est. completion date | February 2024 |
Est. primary completion date | February 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 75 Years |
Eligibility | Inclusion Criteria: - histologically proven primary gastric adenocarcinoma, - T1N0, T1N1, T2N0, which are assessed by computed tomography (CT) scan (AJCC 8th classification) and intraoperative surgical staging - location of primary tumor; antrum, or angle, , lower body or mid body of the stomach - No evidence of other distant metastasis, - age = 20 year old, = 75 year old - no prior or posterior treatment of chemotherapy or radiation therapy against any other malignancies - adequate organ functions defined as indicated below: 1. WBC count: 3000/mm3 ~12,000/mm3, 2. > serum Hemoglobin 8.0 g/dL 3. > serum Platelet 100 000/mm3, 4. < serum AST 100 IU/L, 5. <serum ALT 100 IU/L, 6. < Total Bilirubin 2.0 mg/dL, - written signed informed consent Exclusion Criteria: - active double cancer (synchronous double cancer and metachronous double cancer within five disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer), - gastric remnant cancer - =T3, T4 in surgical staging before resection - N2 or more (number of metastatic lymph nodes =3) in CT scan - histologically rare variants in World Health Organization (WHO) Classification such as Adenosquamous, Hepatoid, Squamous cell, Undifferentiated, neuroendocrine carcinoma and others - pregnant or breast-feeding women, - mental disorder(diagnosed with mental disorder on medical record), - unstable angina or myocardial infarction within 6 months of the trial, - unstable hypertension, - diabetes mellitus on insulin, - severe respiratory disease requiring continuous oxygen therapy, - previous upper abdominal surgery except laparoscopic cholecystectomy, - surgical complication |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung medical center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from preoperative weight change at immediate postoperative period in SE and IE groups. | comparison of weight change between the two groups after surgery | preoperative, immediate postoperative | |
Primary | Change from preoperative weight change at postoperaive 1 month in SE and IE groups. | comparison of weight change between the two groups after surgery | preoperative, postoperative 1 month | |
Primary | Change from preoperative weight change at postoperaive 3 months in SE and IE groups. | comparison of weight change between the two groups after surgery | preoperative, postoperative 3 months | |
Primary | Change from preoperative weight change at postoperaive 6 months in SE and IE groups. | comparison of weight change between the two groups after surgery | preoperative, postoperative 6 months | |
Primary | Change from preoperative weight change at postoperaive 12 months in SE and IE groups. | comparison of weight change between the two groups after surgery | preoperative, postoperative 12 months | |
Primary | Change from preoperative weight change at postoperaive 18 months in SE and IE groups. | comparison of weight change between the two groups after surgery | preoperative, postoperative 18 months | |
Secondary | Nutritional parameters | measured by Patient-Generated Subjective Global Assessment (PG-SGA; rating A,B,C) | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | 24hrs dietary recall | calculating kcal & protein intake by 24hrs dietary recall (questionnaire) | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | dietary habits | number of meals, eating speed (questionnaire) | preoperative, immediate postoperative, postoperative 1 months, 3 months, 6months, 12 months, 18 months | |
Secondary | Albumin | g/dL | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | Hemoglobin | g/dL | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | Total iron binding capacity (TIBC) | µg/dL | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | Ferritin | ng/mL | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | Absolute lymphocyte count (ALC) | 10^3/µL | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | Vitamin B12 | pg/mL | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | Homocysteine | µmol/L | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months | |
Secondary | Quality of life of the patients | European quality of life questionnaire (EQ-5D); the descriptive system which comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems (labelled 1-3). | preoperative, immediate postoperative, postoperative 1 month, 3 months, 6months, 12 months, 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |